ICH analytical method validation using Q2(R2) and Q14 together
ICH analytical method validation uses Q2(R2) to show fitness for purpose, with Q14 guiding development. Plan the protocol, relevant tests and report.
ICH analytical method validation demonstrates that an analytical procedure is fit for its intended purpose under Q2(R2). Use Q14 alongside it to connect procedure development with the validation study and ongoing procedure controls. Both guidelines cover new or revised procedures for commercial drug-substance and drug-product release and stability testing. (Q2(R2) scope, Q14 scope)
Start with the measurement you need, then choose the evidence that will show the procedure can deliver it. Q2(R2) calls for a protocol before the study and a report summarising the results. It does not make one fixed set of tests suitable for every procedure. (ICH Q2(R2), section 2.1)
How ICH Q2(R2) and Q14 fit together
Q2(R2) provides the general validation framework, including analytical use of spectroscopic data. Q14 addresses science- and risk-based procedure development and maintenance. Use development knowledge to shape the validation strategy and study design. (FDA Q2(R2), FDA Q14, ICH quality guidelines)
Their activities can overlap. Q14 allows the order and extent of development activities to vary, with some occurring simultaneously. But the procedure control strategy should be defined before validation and confirmed once validation is complete. (ICH Q14, section 6)
If your reference is ICH Q2(R1), use the current Q2(R2) listing when planning a study. The ICH listing links to a 2025 error-corrected Q2(R2) file. Neither an older version nor a draft should stand in for that text. (Current ICH quality guidelines)
Build the validation study around its intended purpose
Define the measurement and performance criteria
State what the procedure must measure and how the result will be used. Q2(R2) covers purposes such as identity, assay or potency, purity and impurities. It also addresses other quantitative and qualitative measurements. The intended purpose and selected technology determine the suitable performance characteristics and their criteria. (EMA Q2(R2), ICH Q2(R2), section 2.1)
Make that decision before choosing experiments. A copied parameter list does not explain why the planned evidence suits your procedure. Record the link between the intended measurement, the characteristics selected and the criteria you will use to assess them. (ICH Q2(R2), section 2.1)
Bring development knowledge into the protocol
Use development findings to shape the validation study. Where you rely on prior knowledge from development or previous studies, justify its use. The protocol should state the intended purpose, the performance characteristics to validate and the associated criteria. (ICH Q2(R2), section 2.1)
Check the procedure description too. Q14 says it should let a skilled analyst perform the analysis and interpret the results. Relevant details can include preparation, materials, apparatus, calibration, replicates and calculations. A study plan needs a sufficiently clear procedure behind it. (ICH Q14, section 6)
Match the study design to the routine result
Plan the experimental design around the replicate scheme used for the routine reportable result. Q2(R2) permits justified differences or adjustments, so do not read this as an absolute requirement for identical replicate counts. Explain the design choice in the study documentation. (ICH Q2(R2), section 2.1)
After the study, summarise the results in a validation report. Present the evidence against the objectives and criteria set for the procedure. The purpose is to demonstrate fitness for use, not merely to record that experiments took place. (ICH Q2(R2), section 2.1)
Which validation parameters should you assess?
When planning the study, consider specificity/selectivity, response and range, accuracy, precision, detection limit (LOD) and quantitation limit (LOQ). Select the characteristics relevant to the intended measurement. Not every characteristic is required for every procedure. Consult the current Q2(R2) tables and section 3 for detailed test selection. (ICH Q2(R2))
For response, linearity and range, choose performance criteria that suit the purpose and technology. For accuracy and precision, specify the relevant characteristics and acceptance criteria before the study. Check whether detection and quantitation limits are relevant instead of assuming both belong in every protocol. (ICH Q2(R2), section 2.1)
A generic spreadsheet can obscure which criteria your procedure needs. Do not present a generic correlation threshold, recovery percentage or RSD limit as an ICH-wide acceptance rule. Section 2.1 ties criteria to purpose and technology, and the examples in Annex 2 are non-binding. (ICH Q2(R2))
Put robustness and system suitability in the right place
Robustness is typically evaluated during development, before the validation study. Those findings help inform validation and the procedure control strategy. Q14 describes that strategy as drawing on procedure understanding, risk assessment, development data, robustness and prior knowledge. (ICH Q2(R2), section 2, and Q14, section 6)
System suitability is an integral part of the procedure and is generally established during development. It provides a regular performance check during analysis. The validity of results depends on its outcome, but passing system suitability does not replace the initial validation study. (ICH Q2(R2), section 2.1, and Q14, section 6)
Check the guidance status for your market
FDA issued final Q2(R2) and Q14 guidance in March 2024. EMA gives 14 June 2024 as the effective date for both. Do not use that EU date as a UK implementation deadline. (FDA Q2(R2), FDA Q14, EMA Q2(R2), EMA Q14)
For procedures already approved, Q14 supports science- and risk-based change management when scientifically justified. It is not automatic permission to change an approved procedure without regulatory consideration. (FDA Q14)
RegAffairs AI's answer on ICH analytical method validation shows how Q2(R2) and Q14 fit together.